(Q36563414)

14 August 2017

1 reference

title

VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases (English)

1 reference

inflammatory bowel diseases

14 August 2017

0 references

0 references

0 references

2

Greg L Plosker

1 reference

14 August 2017

3

David P Figgitt

1 reference

14 August 2017

Therese M Chapman

1

1 reference

14 August 2017

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

66

1 reference

14 August 2017

10

1 reference

14 August 2017

1371-1387

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200666100-00006

14 August 2017

0 references

cites work

Effects of probiotic on intestinal mucosa of patients with ulcerative colitis

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200666100-00006

Probiotics and the management of inflammatory bowel disease.

21 January 2018

1 reference

12 December 2020

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

1 reference

12 December 2020

Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora

1 reference

12 December 2020

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

1 reference

12 December 2020

Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis

1 reference

12 December 2020

Probiotic bacteria enhance murine and human intestinal epithelial barrier function

1 reference

12 December 2020

Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment.

1 reference

12 December 2020

Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

1 reference

12 December 2020

Beclomethasone dipropionate plus VSL#3 for the treatment of mild to moderate diverticular colitis: an open, pilot study

1 reference

12 December 2020

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

1 reference

12 December 2020

A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome

1 reference

12 December 2020

Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea

1 reference

12 December 2020

Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells

1 reference

12 December 2020

Epidemiology of inflammatory bowel disease in Italy.

1 reference

12 December 2020

DNA from probiotic bacteria modulates murine and human epithelial and immune function.

1 reference

12 December 2020

Use of probiotics in the treatment of inflammatory bowel disease

1 reference

12 December 2020

Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation

1 reference

12 December 2020

Probiotics and prebiotics in gastrointestinal disorders.

1 reference

12 December 2020

Behaviour of the pharmaceutical probiotic preparation VSL#3 in human ileostomy effluent containing its own natural elements

1 reference

12 December 2020

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

1 reference

12 December 2020

Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells

1 reference

12 December 2020

Diagnosis and treatment of patients with pouchitis

1 reference

12 December 2020

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

1 reference

12 December 2020

Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis.

1 reference

12 December 2020

Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases.

1 reference

12 December 2020

Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

1 reference

12 December 2020

Guidelines for the management of inflammatory bowel disease in adults

1 reference

12 December 2020

PCR detection of Bifidobacterium strains and Streptococcus thermophilus in feces of human subjects after oral bacteriotherapy and yogurt consumption

1 reference

12 December 2020

Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative?

1 reference

12 December 2020

Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression

1 reference

12 December 2020

A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating

1 reference

12 December 2020

Prevention is the best defense: probiotic prophylaxis of pouchitis

1 reference

12 December 2020

Comparative composition of bacteria in the human intestinal microflora during remission and active ulcerative colitis

1 reference

12 December 2020

Functional modulation of enterocytes by gram-positive and gram-negative microorganisms

1 reference

12 December 2020

Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition

1 reference

12 December 2020

Modulation of human dendritic cell phenotype and function by probiotic bacteria

1 reference

12 December 2020

Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.

1 reference

12 December 2020

Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.

1 reference

12 December 2020

VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

1 reference

12 December 2020

A pilot trial of Saccharomyces boulardii in ulcerative colitis

1 reference

12 December 2020

Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

1 reference

12 December 2020

Probiotics and inflammatory bowel disease: is there a scientific rationale?

1 reference

12 December 2020

Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression.

1 reference

12 December 2020

1 reference

12 December 2020

10.2165/00003495-200666100-00006

Identifiers

DOI

1 reference

PubMed ID

16903771

Dimensions Publication ID

14 August 2017

1012272699

0 references

Fatcat ID

release_urqsefabu5ae3cd23cdfsffhcm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/urqsefabu5ae3cd23cdfsffhcm

24 November 2022

mapped directly with Wikidata item

PubMed ID

16903771

1 reference

PubMed ID

16903771